Meetings By Mail Cleveland Clinic Cardiovascular Update 2025
$21
Meetings By Mail Cleveland Clinic Cardiovascular Update 2025
Include: 50 videos, size: 3.86 GB
Release Date: 1/15/25
Cleveland Clinic Cardiovascular Update incorporates the latest science and clinical best practices to improve cardiovascular disease prevention, care and outcomes. A world class faculty delivers essential educational content emphasizing cutting edge advances, the implementation of evidence-based guidelines and the promotion of health equity among diverse populations. Application of the lessons discussed throughout this activity should result in improved cardiovascular outcomes for patients.
Topics include:Essentials of cardiovascular disease, structural heart disease, ischemia, aortic stenosis, tricuspid regurgitation, hypertrophic cardiomyopathy, heart failure, atrial fibrillation, syncope, statins, dietary impact, pharmacotherapy, hypertension, special populations, hormone therapy, rehab, peripheral artery disease, pacemakers, wearables and much more!
The Meetings By Mail Cleveland Clinic Cardiovascular Update 2025 is designed for healthcare professionals involved in cardiovascular care. This includes:
- General Cardiologists: To stay updated on the latest advancements in cardiovascular disease prevention and management.
- Primary Care Providers: For insights into managing cardiovascular risks in diverse patient populations.
- Internal Medicine Specialists: To enhance their understanding of cardiovascular conditions and treatments.
- Nurse Practitioners and Physician Assistants: Focused on improving patient outcomes in cardiovascular care.
- Residents and Fellows: Seeking to deepen their knowledge in cardiology.
- Pharmacists and Nurses: Interested in the latest evidence-based practices for cardiovascular health.
This program emphasizes cutting-edge advances, evidence-based guidelines, and promoting health equity among diverse populations.
Cleveland Clinic
Cardiovascular Update
| Session 1: Prevention and Management of Cardiovascular Risk, Part 1 | |
| Tools in CVD Prevention and Risk Management: To Test or Not to Test? Lp(a),apoB, Non HDL-C | Dennis Bruemmer, MD, PhD |
| Statin Initiation for Primary Prevention Among Statin Naïve Adults and Reasons for Nonadherence | Vikas Sunder, MD |
| When Statins Are Not Enough – Non-statin Lipid Lowering Therapies to Manage Residual Risk | Ashish Sarraju, MD |
| Managing Anti-Hyperglycemic and CV Risk Reduction Agents in Patients With Diabetes: SGLT2i or GLP1RA or Both? | Dennis Bruemmer, MD, PhD |
| Weight Loss Pharmacotherapy: Utilizing Current Therapies and Exploring the Next Generation of Weight Loss Medications | Steve Nissen, MD |
| Keto, Low Carb, Plant Based, IF: Controversies in the Evidence for the “Best “Diet: What is the Evidence and How to Apply in Clinical Practice | Julia Zumpano, RD, LD |
| Old and Evolving Strategies for Treatment-Resistant Hypertension | Luke Laffin, MD |
| Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions | Lee Kirksey, MD |
| Panel Discussion/Q&A | Session Faculty |
| Session 2: Prevention and Management of Cardiovascular Risk, Part 2 | |
| Hormone Therapy and Heart Health: Debunking Myths, Embracing Evidence | Luke Laffin, MD |
| The Intersection of Cardiovascular Disease and Chronic Kidney Disease: Strategies for Reducing Cardiovascular Risk | Crystal Gadegbeku, MD |
| Who Should Get a CAC? How Often? How to Use the Results to Assess Risk? | Milind Desai, MD |
| Management of CV Issues in the Elderly: Geriatric Cardiology | Ardeshir Hashmi, MD |
| Population Health Management: Interventions to Control Cardiovascular Disease Risk Factors: Current Status | LeRoi Hicks, MD |
| Panel Discussion/Q&A | Session Faculty |
| Session 3: Special Populations | |
| Cardiac Disease Remains the Leading Cause of Mortality in Women: What are we Doing to Address This? | Vikas Sunder, MD |
| Cardiovascular Disease and Pregnancy: Optimizing Maternal and Fetal Health | Deirdre Mattina, MD |
| Competitive Sports Participation in Athletes with Heart Disease: Evaluation and Management | Tamanna Singh, MD |
| Cardio-oncology: Optimizing the Balance Between Cancer Outcomes and Cardiac Success | Patrick Collier, MD, PhD |
| Panel Discussion/Q&A | Session Faculty |
| Session 4: Essentials of Cardiovascular Disease | |
| Role of Advanced Imaging for Ischemic Heart Disease: CT, CMR, Nuclear and Advanced Echocardiography | Saberio Lo Presti Vega, MD |
| Creating a Pathway for the Management of Stable Angina in Your Clinic: Structured Risk Assessment and Clinical Decision Making | Ben Alencherry, MD |
| ANOCA, INOCA, MINOCA: What Does It All Mean? Diagnostic Testing and Therapeutic Management | Khalid Ziada, MD |
| How Do I Manage my Post MI Patient (Including DAPT Guidelines/Duration/CardiacRehab) | Venu Menon, MD |
| Cardiac Rehab: Why it is Critical and How Can We Improve Access and Compliance? | Erik Van Iterson, PhD, MS |
| Peripheral Artery Disease: Assessment and Clinical Decision Making | Lee Kirksey, MD |
| Panel Discussion/Q&A | Session Faculty |
| Session 5: Structural Heart Disease | |
| Aortic Stenosis: Diagnosis and Management in the Modern Era | Samir Kapadia, MD |
| MR: How to Diagnose and Manage Mitral Valve Disease: When to Refer? What are the Options | L. Leonardo Rodriguez, MD |
| What to Know About the Natural History of Tricuspid Regurgitation: Current and Future Management Strategies | Amar Krishnaswamy, MD |
| Bicuspid and Aneurysm-Associated Aortic Valve Disease: Timing of Intervention and the Role of Family Screening | Milind Desai, MD |
| Guidelines for Anticoagulation Following Structural Heart Therapies | Grant Reed, MD, MSc |
| Hypertrophic Cardiomyopathy: Co-management in the Era of Emerging Precision Therapies | Milind Desai, MD |
| Panel Discussion/Q&A | Session Faculty |
| Session 6: Heart Failure | |
| Heart Failure Stages, Phenotypes and Diagnosis and How to Screen for HF in the Primary Care Setting | Randall Starling, MD |
| HFrEF: Essentials of Guideline Directed Medical Therapy Initiation and Titration | Amanda Vest, MBBS |
| Managing Comorbidities in HF: Frailty, Anemia, Sleep Apnea, AF, Obesity | Karlee Hoffman, DO |
| Essentials of Diagnosis and Management for HFpEF | Sanjeeb Bhattacharya, MD |
| Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Mazen Hanna, MD |
| Strategies to Enhance GDMT Implementation and Adherence | M. Trejeeve Martyn, MD |
| Managing Long Term LVADs and Transplant Recipients in the Community Setting | Ike Okwuosa, MD |
| The Importance of Collaboration Between EP and HF: CRT and Novel Pacing | Niraj Varma, MD, PhD |
| Panel Discussion/Q&A | Session Faculty |
| Session 7: Heart Rhythm | |
| Diagnosis and Management of New-Onset Atrial Fibrillation | Mohamed Kanj, MD |
| AF and Left Atrial Appendage Closure: Current and Future Directions | Mohamed Kanj, MD |
| What I Need to Know to Evaluate and Manage the Patient With PVCs and SVT | Pasquale Santangeli, MD, PhD |
| Evaluation and Management of Syncope in the Young Adult | Kenneth Mayuga, MD |
| Follow-Up of Pacemakers and ICDs For the Non-Electrophysiologist | Kevin F. Kwaku, MD, PhD |
| Wearables for Arrhythmia Care: Current Challenges and Future Prospects | Niraj Varma, MD, PhD |
| Panel Discussion/Q&A | Session Faculty |
End
Topics:
1 Tools in CVD Prevention and Risk Management To Test or Not to Test Lp(a),apoB, Non HDL-C.mp4
2 Statin Initiation for Primary Prevention Among Statin Na‹ve Adults and Reasons for Nonadherence.mp4
3 When Statins Are Not Enough – Non-statin Lipid Lowering Therapies to Manage Residual Risk.mp4
4 Managing Anti-Hyperglycemic and CV Risk Reduction Agents in Patients With Diabetes SGLT2i or GLP1RA or Both.mp4
5 Weight Loss Pharmacotherapy Utilizing Current Therapies and Exploring the Next Generation of Weight Loss Medications.mp4
6 Keto, Low Carb, Plant Based, IF Controversies in the Evidence for the “Best “Diet What is the Evidence and How to Apply in Clinical Practice.mp4
7 Old and Evolving Strategies for Treatment-Resistant Hypertension.mp4
8 Social Determinants of Health and Cardiovascular Disease Current State and Future Directions.mp4
9 Panel DiscussionQ&A.mp4
10 Hormone Therapy and Heart Health Debunking Myths, Embracing Evidence.mp4
11 The Intersection of Cardiovascular Disease and Chronic Kidney Disease Strategies for Reducing Cardiovascular Risk.mp4
12 Who Should Get a CAC How Often How to Use the Results to Assess Risk.mp4
13 Management of CV Issues in the Elderly Geriatric Cardiology.mp4
14 Population Health Management Interventions to Control Cardiovascular Disease Risk Factors Current Status.mp4
15 Panel DiscussionQ&A.mp4
16 Cardiac Disease Remains the Leading Cause of Mortality in Women What are we Doing to Address This.mp4
17 Cardiovascular Disease and Pregnancy Optimizing Maternal and Fetal Health.mp4
18 Competitive Sports Participation in Athletes with Heart Disease Evaluation and Management.mp4
19 Cardio-oncology Optimizing the Balance Between Cancer Outcomes and Cardiac Success.mp4
20 Panel DiscussionQ&A.mp4
21 Role of Advanced Imaging for Ischemic Heart Disease CT, CMR, Nuclear and Advanced Echocardiography.mp4
22 Creating a Pathway for the Management of Stable Angina in Your Clinic Structured Risk Assessment and Clinical Decision Making.mp4
23 ANOCA, INOCA, MINOCA What Does It All Mean Diagnostic Testing and Therapeutic Management.mp4
24 How Do I Manage my Post MI Patient (Including DAPT GuidelinesDurationCardiacRehab).mp4
25 Cardiac Rehab Why it is Critical and How Can We Improve Access and Compliance.mp4
26 Peripheral Artery Disease Assessment and Clinical Decision Making.mp4
27 Panel DiscussionQ&A.mp4
28 Aortic Stenosis Diagnosis and Management in the Modern Era.mp4
29 MR How to Diagnose and Manage Mitral Valve Disease When to Refer What are the Options.mp4
30 What to Know About the Natural History of Tricuspid Regurgitation Current and Future Management Strategies.mp4
31 Bicuspid and Aneurysm-Associated Aortic Valve Disease Timing of Intervention and the Role of Family Screening.mp4
32 Guidelines for Anticoagulation Following Structural Heart Therapies.mp4
33 Hypertrophic Cardiomyopathy Co-management in the Era of Emerging Precision Therapies.mp4
34 Panel DiscussionQ&A.mp4
35 Heart Failure Stages, Phenotypes and Diagnosis and How to Screen for HF in the Primary Care Setting.mp4
36 HFrEF Essentials of Guideline Directed Medical Therapy Initiation and Titration.mp4
37 Managing Comorbidities in HF Frailty, Anemia, Sleep Apnea, AF, Obesity.mp4
38 Essentials of Diagnosis and Management for HFpEF.mp4
39 Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM).mp4
40 Strategies to Enhance GDMT Implementation and Adherence.mp4
41 Managing Long Term LVADs and Transplant Recipients in the Community Setting.mp4
42 The Importance of Collaboration Between EP and HF CRT and Novel Pacing.mp4
43 Panel DiscussionQ&A.mp4
44 Diagnosis and Management of New-Onset Atrial Fibrillation.mp4
45 AF and Left Atrial Appendage Closure Current and Future Directions.mp4
46 What I Need to Know to Evaluate and Manage the Patient With PVCs and SVT.mp4
47 Evaluation and Management of Syncope in the Young Adult.mp4
48 Follow-Up of Pacemakers and ICDs For the Non-Electrophysiologist.mp4
49 Wearables for Arrhythmia Care Current Challenges and Future Prospects.mp4
50 Panel DiscussionQ&A.mp4
Related products
